The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
National Comprehensive Cancer Network.Clinical Practice Guidelines – non-small-cell lung cancer. v.2. 2011. National Comprehensive Cancer Network Web site. http://www.nccn.org. Accessed December 20, 2010.
2.
VokesE.E., HerndonJ.E.II, KelleyM.J.Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol.2007; 25(13): 1698–1704.
3.
YamamotoN., NakagawaK., NishimuraY.Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol.2010; 28(23): 3739–3745.
4.
SchuetteW., BlankenburgT., GuschallW.Multicenter randomized trial for stage IIIB/IV non-small-cell lung cancer using every-3-week versus weekly paclitaxel/carboplatin. Clin Lung Cancer.2006; 7(5): 338–343.
5.
BelaniC.P., BarstisJ., PerryM.C.Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol.2003; 21(15): 2933–2939.
6.
National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology - antiemesis. v.1.2011. National Comprehensive Cancer Network Web site. http://www.nccn.org. Accessed December 23, 2010.
7.
TerreyJ.P., AaproM.S.The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res.1996; 8: 281–288.
8.
CarmichaelJ., KeizerH.J., CupissolD., MilliezJ., ScheidelP., SchindlerA.E.Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs.1998; 9(5): 381–385.
9.
de WitR., de BoerA.C., LindenG.H., StoterG., SparreboomA., VerweijJ.Effective cross-over to granisetron after failure to ondansetron, a randomized double-blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer.2001; 85(8): 1099–1101.
10.
SmithI.E.A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol.1993; 119(6): 350–354.
11.
SoukopM.A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer.1994; 2(3): 177–183.
National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology – myeloid growth factors. v.1.2010. National Comprehensive Cancer Network Web site. http://www.nccn.org. Accessed December 24, 2010.
15.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury. Hosp Pharm.2000; 35(1): 57–74.
16.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21(1): 33–64.
17.
WaddellJ.A., SolimandoD.A.Verifying carboplatin dose calculations in adult patients with the Calvert and modified Calvert formulas. Hosp Pharm.2000; 35(9): 914–922.
18.
FloydJ., MirzaI., SachsB., PerryM.C.Hepatotoxicity of chemotherapy. Semin Oncol.2006; 33(1): 50–67.
